23andMe: a Risky Healthcare Technology Company With Substantial Upside

Equity Analyst

Dylan Finley

23andMe primarily sells direct-to-consumer personal genome service, or PGS, kits, analyzing specific genetic components (single nucleotide polymorphisms, or SNPs), to approximate genetic ancestry, predisposition to physical traits, and presence of genetic disease variants. The company leverages third party manufacturers for kit components, including the genotype array chip used to analyze the genetic material, and processes the samples on site at LabCorp locations. 12andMe has sequenced the genome of over 12 million individuals, over 80% of whom have opted in to sharing their de-identified genetic data and research survey responses with the company. 23andMe and privately held Ancestry.com hold a dominant share of the direct-to-consumer PGS market due to an early mover advantage, brand awareness, and database size. 

A recent slowdown in kit sales has drawn concerns over the long-term size of the addressable market. As it currently stands, many of the available reports serve more of a novelty purpose, and while the company might identify specific genetic variants corresponding with disease, the SNPs looked at are not comprehensive enough on their own to be a complete substitute for whole genome sequencing (in instances where that is desired by a medical provider). Despite this, the company possesses a massive database of genetic data and an active base of respondents to research questions, which are used to better understand the relationship between the human genome and health characteristics in academic research and commercial drug development. 

The company hopes to use its data to more quickly and efficiently develop therapeutics, particularly in the biotech space, and has attracted interest from manufacturers. In 2018, GlaxoSmithKline made a $300 million equity investment in the company, entering a five-year exclusive collaborative agreement with 23andMe to develop drug candidates. All current candidates are in Phase 1 or preclinical stages of development.

Business Strategy & Outlook

Despite being the pioneer of a model for direct-to-consumer genetic data services, the lack of meaningful barriers to entry in the space and presence of competitor ancestry and health-related gene testing kits preclude the company from establishing an economic moat. 

23andMe primarily generates revenue today through the sale of personal genome service, or PGS, kits. Consumers who purchase a kit provide the company with a saliva sample, from which DNA is isolated. The company uses a technology called genotype imputation, only analyzing a tiny fraction of an individual’s genome, which exhibits known variances in human populations and results in phenotypic (physical characteristic) differences, predisposition to disease, and correlation with other health-related characteristics. In the lab, the genetic material is tested on genotype array chips, which read several hundred thousand single nucleotide polymorphisms, or SNPs, in the sample. Most other competitor DTC companies that offer PGS services use this same process, opting for genotype imputation over whole genome sequencing, due to the very low cost incurred per sample. While whole-genome sequencing has made enormous strides in cost and efficiency since the human genome project was effectively completed in 2003 (13 years of research; costing nearly $3 billion), the cost to sequence a whole genome remains prohibitively high today for most individuals, at around $1000 per sample. By contrast, genotype sampling costs a fraction of that amount. While the technology could follow Moore’s law in the future and become more cost-effective over time, the added benefits of using full genome sequencing in a DTC offering are dubious. Our current state of knowledge of the human genome is extremely limited, and consumers and DTC companies wouldn’t be able to glean any deeper insights as a result of sequencing the whole genome anytime soon. 

To date, over 30 million consumers have used DTC testing kits worldwide, with the vast majority using 23andMe and AncestryDNA (Ancestry.com) over the dozens of smaller competitors. We attribute the high market share concertation between these two companies to superior brand awareness, database size, and availability. Despite, these competitive advantages, two factors preclude us from attributing a moat to the company: (1) a secular decline of kit sales in recent years, confirming fears that the addressable market for PGS is somewhat niche; and (2) the spike in sales around times when genetic testing companies offer steep discounts (for example, Amazon’s Prime Day, winter holiday period) suggests to us that consumers are generally price-sensitive and the company’s pricing power is limited. Furthermore, the company’s primary revenue stream is non-recurring, leaving no room to build up brand loyalty or switching costs within its existing customer base. By contrast, privately owned Ancestry.com has over 3 million subscription-based customers, primarily as a result of their focus on genealogical resources (billions of historical records; hundreds of millions of user generated family trees and user-uploaded photos and documents). While 23andMe has a subscription offering (23andMe+), the added benefits are more marginal than anything--access to several dozen additional disease carrier, wellness, and pharmacogenetic reports. Due to the static nature of these reports (our genome is fixed and reports shouldn’t change), future engagement is limited to instances where the company releases new genetic reports. Consequently, these incremental reports must be compelling enough on their own to move consumers over to this recurring subscription model. 

From a cost advantage or intangible assets standpoint, 23andMe does not have any material competitive advantages in sequencing customers’ genetic data. Similar to other DTC competitors, 23andMe relies on various third parties and labs. The genotyped samples are analyzed at Labcorp facilities in the U.S., using Illumina’s global screening array chip as a base (with some added SNPs of interest). While additional scale allows for the company to achieve a degree of leverage on operating expenses, and contracts with suppliers allow for advantageous pricing based on volume, these benefits are conferred to any kit seller generating meaningful volume. Furthermore, while the company is on the cutting edge of generating actionable insights based off genetic data (that is pharmacogenetic reports), its unclear at this time how valuable these reports are to consumers and whether this will translate into recurring business. For consumers who are primarily interested in the novelty aspect of sequencing their DNA (tracing their predicted roots; viewing trait reports), more detailed health related reports may not be of sufficient interest for consumers to upgrade to the latest version of a chip or pay a premium versus competitors’ offerings. As such, despite any advantage stemming from superior research, the company may continue to act more as a price taker, similar to most other kits on the market

23andMe entered the telehealth space in 2021, with its $400 million acquisition of Lemonaid. The standalone company generates around $60 million in revenue, on an annualized basis from the quarter the deal closed. From a strategic standpoint, the company sees the acquisition as a route to get from consumer genetics services to individualized health care. The status quo for primary care today does not take into account a patient’s genetic data (except in select rare disease cases), and 23andMe sees itself bridging this gap. Our primary concern is the disconnect between the company’s goals and Lemonaid’s offerings as of today. Lemonaid connects consumers with medical professionals via telehealth and delivers select prescription drugs to consumers via mail. The company’s focus is on treatment areas which patients may not actively be seeking out due to stigma (mental health, men and women’s reproductive health). Lemonaid offers primary care services via a monthly fee, which is not reimbursed by medical insurance. In the near-term, the acquisition does not provide for any meaningful synergies or enhance the competitive positioning of the company’s PGS business. From a primary care perspective, the company’s primary challenge will be educating telehealth providers on offering a new type of health care which combines traditional care tailored to specific genetic insights. 

Lastly, the company’s therapeutics segment is too far in its infancy for us to consider and economic moat. The company has dozens of drug candidates in very early development stages and is still several years away from having a commercially viable therapy. The value proposition of using genetic inferences to most efficiently find targets (particularly in the realm of biologics), is of high interest to biopharma firms. The company’s five-year agreement with GlaxoSmithKline currently has the company locked in an exclusive arrangement through 2023, after which we could see the company taking on several partners on a nonexclusive basis. We are a bit hesitant of the company’s ability to develop and take to market a drug on their own at this stage due to the capital intensity. While 23andMe has a large amount of cash on its balance sheet, the cash flow dilutive nature of its core business, and the company could get more value in the near term by continuing with 50/50 partnerships or by electing to take royalties from collaborative projects.

None

Economic Moat

23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.

23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies 23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies

23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2023 Annual Meeting

23andMe's quarterly revenues have slightly decreased due to lower volumes sold, but there is still a market for its Personal Genome Service kit. The company has a massive data set that it is hoping to turn into usable therapies for various diseases. The most promising is undergoing clinical trials. 23andMe could now potentially partner up with other major pharmaceutical companies and biotech firms to leverage the company's massive genetic dataset.

23andMe: Hidden Therapeutics Asset

23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell disease is common

23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program

BioVie Inc

Galera Therapeutics

iSpecimen

Singular Genomics Systems

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

Shares of 23andMe Holding Co. ME, -4.35% jumped 23% in the extended session Thursday after the genetics and biopharmaceutical company said that the U.S. Food and Drug Administration has cleared it to add more gene variants to the company's direct-to-consumer health reports on genetic risks for certain cancers. The 41 gene variants in question are associated with higher risk for breast, ovarian, prostate, pancreatic, and potentially other cancers, 23andMe said.

23andMe stock rallies more than 23% after genetics company gets OK to report more cancer risks

510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Recursion Pharmaceuticals

AI for drug development is very fashionable in biotech, and for good reason. 23andMe's consumer business could one day provide a bedrock of stability.

Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe

The genetics specialist notched a double miss with its latest earnings report. It seems this fiscal year will be worse than its predecessor for headline fundamentals.

Why 23andMe Holding Stock Plummeted by 13% Today

23andMe Holding Co. (NASDAQ:ME ) Q1 2024 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Katie Watson - Vice President of Communications Anne Wojcicki - Chief Executive Officer and Co-Founder Joe Selsavage - Interim Chief Financial and Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants David Lebowitz - Citi Gaurav Goparaju - Berenberg Capital Markets Operator Hello, and welcome to 23andMe's Fiscal Year 2024 First Quarter Financial Results Conference Call. As a reminder, this call is being recorded.

23andMe Holding Co. (ME) Q1 2024 Earnings Call Transcript

Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit

23andMe Reports FY2024 First Quarter Financial Results

NEW YORK , July 31, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of 23andMe Holding Co. (NASDAQ: ME). If you are a shareholder of 23andMe Holding Co. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/23andme-holding-co/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating 23andMe Holding Co. for Potential Breaches of Fiduciary Duty By Its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) first quarter after the market closes on Tuesday, August 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2024 First Quarter Financial Results

23andMe is the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports, with medication insights

23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin

Shake Shack

Shares of upscale burger chain Shake Shack have wiped out last year's losses, while 23andMe stock set a record low.

Shake Shack Stock Blows Through the Roof. 23andMe Tumbles.

With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of these conditions With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of these conditions

23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks

Illumina

Myriad Genetics

Genes are the foundation of human life. They are the code that gives every instruction to our bodies about how to move, digest and think.

3 Gene Testing Stocks to Buy Before They Take Off

23andMe entered its IPO with two down years on revenue but has since reclaimed low double-digit growth. Throughout this time, however, the company has not made identifiable progress toward profitability on either an accrual or cash basis. It continues to use cash from the IPO for operations. This makes for a hold rating even though it is operating in a significant growth market, consumer genetics testing, that has a CAGR of over 20%.

23andMe: Revenue Growth And Secular Trend, But Lack Of Profits Makes It A Hold

23andMe Holding Co. (NASDAQ:ME ) Q4 2023 Results Conference Call May 25, 2023 4:30 PM ET Company Participants Maeve Conneighton - Investor Relations at Argo Partners Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Interim Chief Financial Officer & Accounting Officer Kenneth Hillan - Chief Therapeutics Officer Conference Call Participants Daniel Grosslight - Citi Steven Mah - Cowen Operator Hello, and welcome to 23andMe's Fiscal Year 2023 Fourth Quarter and Full Year Financial Results Conference Call. As a reminder, this call is being recorded.

23andMe Holding Co. (ME) Q4 2023 Earnings Call Transcript

Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

Fulgent Genetics

23andMe is scaling up its pipeline with the help of its collaborators. Fulgent Genetics is rapidly building its oncology testing business.

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

Ginkgo Bioworks Holdings

Schrodinger 

Artificial intelligence is becoming an important value-add for collaborations. Some companies are pursuing collaboration-targeted business models.

3 Key Biotech Trends for 2023 And Beyond

Bionano Genomics

Precigen

High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.

Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich

66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient's complete health picture

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market closes on Thursday, May 25, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.

23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

23andMe+ members can now gain insights on the chronic autoimmune condition 23andMe+ members can now gain insights on the chronic autoimmune condition

News for 23andMe Stock (ME)